Design, synthesis, and evaluation of novel heteroaryldihydropyrimidine derivatives as non‐nucleoside hepatitis B virus inhibitors by exploring the solvent‐exposed region
Citations Over TimeTop 17% of 2019 papers
Abstract
In continuation of our efforts toward the discovery of potent non-nucleoside hepatitis B virus (HBV) inhibitors with novel structures, we have explored the solvent-exposed protein region of heteroaryldihydropyrimidine derivatives. Herein, the morpholine ring of GLS4 was replaced with substituted sulfonamides and triazoles to generate novel non-nucleoside HBV inhibitors with desirable potency. In in vitro biological evaluation, several derivatives showed good anti-HBV DNA replication activity compared to lamivudine. In particular, compound II-1 displayed the most potent activity against HBV DNA replication (IC50 = 0.35 ± 0.04 μM). The preliminary structure-activity relationships of the new compounds were summarized, which may help in discovering more potent anti-HBV agents via rational drug design.
Related Papers
- → Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan(2023)8 cited
- INFANT HEPATITIS SYNDROME(1993)
- → Prävalenzbestimmung von Hepatitis G Virus in Plasmapools und Plasmapoolpräparaten. Prevalence of Hepatitis G Virus in Plasma Pools and Products(2000)
- → Control of Hepatitis in Hospital(1998)
- → 5607851 Process for purifying hepatitis a virus (HAV), and vaccine compositions containing hepatitis A virus(1997)